AngioJet ZelanteDVT Thrombectomy Catheter

Boston Scientific Corporation
(508) 650-8000
www.bostonscientific.com/zelantedvt

KEY FEATURES

• 8-F (2.7-mm) catheter
• Thrombus removal in veins ≥ 6 mm
• Single, larger inflow window
• Power Pulse lytic delivery enabled
• Over-the-wire 0.035-inch guidewire

Boston Scientific Corporation has received both US Food and Drug Administration and European CE Mark approval for the AngioJet ZelanteDVT thrombectomy catheter, a new AngioJet catheter purpose-built to treat deep vein thrombosis. This 8-F (2.7-mm) catheter is the largest and strongest thrombectomy catheter in the AngioJet portfolio, designed to remove four times more thrombus versus previous-generation catheters. AngioJet ZelanteDVT is torqueable with one larger 0.09-inch inflow window, enabling users to maximize and direct the thrombus removal power. The catheter design facilitates rapid thrombus removal in large-diameter upper and lower extremity veins ≥ 6 mm in diameter. The ZelanteDVT catheter is 105 cm in length and is Power Pulse enabled for the infusion of physician-specified fluids, including thrombolytic agents. The catheter utilizes an over-the-wire 0.035-inch (0.89-mm) guidewire and an 8-F sheath for delivery.

Turbo-Power Laser Atherectomy Catheter

Spectranetics Corporation
(719) 447-2556
www.spectranetics.com

KEY FEATURES

• Exclusive atherectomy indication for peripheral ISR
• Provides maximum luminal gain
• Proven clinically superior to PTA alone
• Offers remote automatic rotation

The Turbo-Power laser atherectomy catheter has received FDA clearance for the treatment of in-stent restenosis (ISR). Spectranetics is the only company with a femoropopliteal in-stent restenosis indication backed by a first-of-its-kind, large multicenter, prospective randomized trial conducted for the treatment of ISR in the peripheral vasculature. The Turbo-Power laser atherectomy catheter is designed to advance care for patients suffering from peripheral artery disease. Turbo-Power treats at the tip, creating a pilot channel and vaporizing soft and mixed ISR lesions in a single step.

“Patients with ISR present the most challenging real-world cases, with the longest, toughest lesions. Turbo-Power, with its eccentric tip design, delivers maximal luminal gain, allowing far more effective debulking of ISR lesions. The device is backed by level 1 clinical data proving superiority in both safety and efficacy. With proven evidence, Turbo-Power is driving a new standard of care in ISR treatment,” said Craig Walker, MD, President and Medical Director, Cardiovascular Institute of the South.

Pantheris

Avinger, Inc.
(800) 208-2988
www.avinger.com

KEY FEATURES

• Directional atherectomy with OCT-assisted orientation
• 8-F sheath compatibility*
• 130-cm working length*
• 0.014-inch guidewire compatible

* 7-F/110-cm option pending 510(k) clearance

Pantheris is a first-of-its-kind lumivascular atherectomy catheter. The term lumivascular refers to a novel interventional approach where the therapeutic catheter includes a built-in imaging fiber. This provides real-time imaging (using optical coherence tomography, a nonionizing imaging modality) while the catheter is being used to treat certain forms of peripheral artery disease. Lumivascular therapy can help users avoid injury to the artery when addressing arterial disease, while potentially using less radiation. It can also provide key information regarding the surrounding arterial structures. Pantheris has received US Food and Drug Administration clearance to remove plaque (atherectomy) from partially occluded vessels in the peripheral vasculature with a reference diameter of 3 to 7 mm.